Guardant Ordered to Pay 245M in Patent Dispute
A US court ordered Guardant Health to pay 245.2 million dollars to TwinStrand Biosciences and the University of Washington after finding the company infringed DNA sequencing patents. Guardant strongly disagrees with the decision and plans to appeal the ruling.
Xurve View
Insights:
Xurve View
GUARDANT HEALTH INC was ordered by a United States federal court to pay $245.2M in a DNA sequencing patent dispute. The judgment follows a jury verdict finding that the company willfully infringed two patents held by TwinStrand Biosciences and the University of Washington. The ruling covers products that generated about 90% of Guardant's revenue during the infringement period.
